INTRODUCTION
Chronic kidney disease (CKD) is a growing public health problem worldwide and, over the past decade, it has developed into an area of intensive clinical and epidemiological research. Patients with CKD, even at early stages, demonstrate higher risk for the development of cardiovascular disease (CVD), 1, 2 enhancing morbidity and mortality in this population. 3 A variety of traditional cardiovascular risk factors such as hypertension, diabetes, dyslipidemia 2 and non-traditional variables such as endothelial cell dysfunction, 4 inflammation, 2 low vitamin D levels 5, 6 or hyperphosphatemia [7] [8] [9] begin to act very early in the course of CKD, accelerating the pathogenesis of cardiovascular disease. Taking into account that traditional and CKD-specific risk prediction equations explain only a portion of the cardiovascular disease associated with CKD, the search for new risk factors for cardiovascular disease in CKD patients continues.
Atherosclerotic cardiovascular disease is highly prevalent in CKD patients 7 and its progression is closely associated with the progression of CKD. 10 The role of atherosclerosis in the increased cardiovascular mortality in CKD patients seems clear, although its contribution in late stages is controversial. Indeed, there are differences in the type of cardiovascular events and the associated factors along the progression of CKD. Thus, in early stages, there is a high mortality rate due to ischemic events, related to atherosclerosis. 11 However, in dialysis patients most of the deaths seem to be caused by heart failure and sudden cardiac death, although subclinical atherosclerosis appears to be influencing the higher susceptibility of the myocardium of those patients to electrolyte imbalances. 12 Indeed, atheroma burden also independently predicts cardiovascular events in dialysis, and the rate of atherosclerotic plaque formation predicts cardiovascular events in those patients. 13 Therefore, the determination of factors that affect atherosclerosis progression in CKD could lead to therapeutic targets specific for CKD patients.
Fibroblast growth factor 2 (FGF-2 or bFGF) is a member of a large family of heparin-binding proteins 14 that has an important role in the pathogenesis of atherosclerosis, but it also has cardioprotective actions. FGF-2 affects essential biological activities of vascular cells such as differentiation, proliferation and migration, showing a dual role in the cardiovascular system. The expression of FGF-2 and its receptors in a normal vessel wall is highly beneficial for the maintenance of the vascular homeostasis and protection of endothelial cells. 15 However, FGF-2 and its receptors play a role in the inflammatory process, intimal thickening and intra-plaque angiogenesis, 16 stimulating proliferation and migration of vascular smooth muscle cells (VSMC) 14, 17 and development of vasa vasorum in atherosclerotic lesions, 18 therefore accelerating atherosclerotic plaque growth.
There are scarce clinical data investigating the role of circulating levels of FGF-2 in atherosclerosis. Only few studies have demonstrated that levels of FGF-2 did not correlate with carotid obstruction grade 19 or coronary artery calcification in the general population. 4 However, to date, no investigation has been conducted analyzing the role of circulating FGF-2 levels in atheromatosis progression. In the present work, we analyzed the association between FGF-2 and progression of atheromatosis burden in a subpopulation of the the NEFRONA study.
METHODS

Design & study population
The protocol of the study was approved by the ethics committee of each hospital and all patients were included after signing informed consent. This research followed the principles of the Declaration of Helsinki. The design and objectives of the NEFRONA study have been already published in detail. 20, 21 Briefly, 2445 CKD patients (937 in CKD stage 3, 820 in stage 4-5 and 688 in dialysis) without a history of previous cardiovascular disease who were 18-75 years of age were enrolled from 81 Spanish hospitals between October 2009 and June 2011, with a scheduled follow-up visit after 24 months. Patients from the NEFRONA study who had hemodynamically significant stenotic carotid plaque, anklebrachial index (ABI) <0.7 at baseline, a cardiovascular event or received a renal allograft along the 2 year's follow up, or died after the first ultrasound exploration were excluded from the follow-up. Thus, 1555 were followed for 24 months. Out of those, 481 had available plasma samples to measure FGF-2 levels. Samples from the other patients had already been spent to measure other biomarkers in sub-studies within the NEFRONA study. 22, 23 In any case, both populations did not differ in most of the parameters of the study, although there was a lower proportion of patients in dialysis than in the total sample. Consequently, high sensitivity C-reactive protein (hsPCR) levels were lower and 25(OH)D, total and LDL cholesterol levels were higher in the analyzed sample (Supplemental table S1). 
Determination of FGF-2 in plasma samples
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Clinical data and Laboratory examinations
Current health status, medical history, baseline cardiovascular risk factors and drug use information was obtained at baseline. A physical examination was performed, consisting of anthropometric measures, standard vital tests and ABI measurements as previously described. 24 A pathological ABI was described as ≤ 0.9 or ≥ 1.4. Biochemical data were obtained from a routine fasting blood test within three months from the vascular study. Previous and current smokers were classified as ever smokers. Diagnosis of dyslipidemia was obtained from the clinical history. Glomerular filtration rate (GFR) was estimated using the Modification of Diet in Renal Disease Study formula (MDRD-4).
Ultrasound Imaging B-mode ultrasound of the carotid and femoral arteries was performed using the Vivid apparatus (General Electric) equipped with a 6-13 MHz broadband linear array probe as previously described. 25 Briefly, ultrasound imaging was performed with the subjects in a supine position and the head turned 45º contralateral to the side of the probe to evaluate carotid plaques. The presence of atheromatous plaques was defined as a IMT > 1.5 mm protruding into the lumen, according to the ASE Consensus Statement 26 and the Mannheim IMT Consensus. 27 The presence of atheromatous plaques was explored in 10 territories (both internal, bulb and common carotids, and both common and superficial femoral arteries) by a single reader in blinded mode, using semi-automatic software (EchoPAC Dimension, General Electric Healthcare). Therefore, a score from 0 to 10 was assigned to every patient both at basal and at the follow up exploration two years later; 0 meaning no plaques in any territorie and 10 the presence of atheroma plaque in all 10 territories explored. To assess intraobserver reliability, a sample of 20 individuals was measured 3-5 times on different days by a reader unaware of patients' clinical history. An intraclass correlation coefficient of 0.8 was obtained for plaque assessment, indicating very good intraobserver reliability. Intima-media thickness (IMT) was only measured in arterial regions without plaque and calculated as the average between left and right sides. When a territory presented with a plaque, IMT value was censored to be 1.5 mm in that territory. The average of the IMT value of the 10 territories was calculated and presented as the patient's IMT.
Evaluation of Progression
Atheromatosis progression was defined as an increase in the number of territories showing a plaque with respect to the baseline visit, as previously used in the MESA study. 28 The analysis was performed in 10 arterial territories, yielding a score of 1 to 10 both, at the baseline (SB) and at the follow up (SFU) visit. The outcome variable (atheromatosis progression) was defined as an increase in the number of territories with plaque with respect to the basal visit. Thus, if SFU -SB > 0 the patient was assigned to the group of progressors. If SFU -SB = 0 the patient was assigned to the group of nonprogressors. In no patient a negative value of (SFU -SB) was observed.
Statistical analysis
Univariable relationship between the levels of the ten compounds measured in the multiplex analysis with plaque presence and progression at 24 months was analyzed by Student's t test for normally distributed variables, and Mann-Whitney's test in nonparametric analysis. In order to account for the multiple testing problem, Bonferroni's correction was applied. Thus, only p values equal or lower than 0.005 were considered statistically significant in the univariate analysis. Significant variables in univariable analyses and potential confounders were used to develop appropriate multivariable logistic regression models. A forward step procedure was used to build the multivariable model, including the variable showing maximum contribution identifying those patients with 24-month atheromatosis progression, according to the likelihood ratio test (LRT).
Those variables without a statistically significant contribution, but modifying in more than 10% the value of the coefficients of any of the significant variables when removed from the model, were considered confounders and included in the final model. Possible first degree interactions between FGF-2 and different parameters were tested. A statistical significance level of 0.05 was used. A sensitivity analysis using FGF-2 as a categorical variable was also built. All analyses were made using a standard statistical package (SPSS 24.0).
RESULTS
The characteristics of the population, grouped by tertiles of FGF-2, are shown in Table 1 . The median age was 61 years, and the median (p25-p75) plasma FGF-2 levels were 85 (55-138)pg/mL. Table 2 shows the univariable analysis of factors associated with atheromatosis progression. Of the 289 patients that progressed, 157 (54%) did so in one territory, 75 (26%) in two, 36 (13%) in three, 14 (5%) in four, 4 (1%) in five, 2 (0.7%) in six and 1 (0.3%) seven new territories were affected after 24 months. The univariable analysis (table 2) showed that patients in whom atherosclerosis progressed were significantly older, more frequently smokers and with a higher percentage of patients with diabetis and hypertension and had higher blood levels of triglycerides, glucose and hsCRP.
Furthermore, the IMT values and the percentage of patients with plaque at baseline was also higher in progressors.
As seen in Figures 1A and B, FGF-2 levels did not differ among patients with or without plaque at baseline neither between patients with different atheromatosis burden.
However, Figure 1C shows that FGF-2 levels were significantly lower in patients in which atherosclerosis progressed after 2 years of follow-up, compared with patients where the plaque burden remained stable. In addition, FGF-2 levels were significantly lower in patients with more advanced CKD stages (Figure 2 ).
The unadjusted analysis modeling atherosclerosis progression (Table 3, 
DISCUSSION
The present work shows that FGF-2 levels are associated with atherosclerosis progression in CKD patients. This effect is independent of other parameters known to affect the progression of atherosclerosis in CKD like age, the degree of renal function, the levels of cholesterol or the smoking status. Therefore, FGF-2 could be considered as a marker and potential target in atherosclerosis progression in CKD patients.
The role of FGF-2 in atherosclerosis is unclear, and preclinical data show that beneficial and detrimental effects could coexist. On the one hand, FGF-2 may be deleterious due to its potential to increase plaque size. Thus, FGF-2 and FGF receptors are expressed in VSMC 29 and FGF-2 induces VSMC proliferation in vitro. 17 Furthermore, FGF-2 promotes VSMC migration by inducing matrix metalloproteases (MMP) 2 and 9 expression in baboon aortic explants 30 and by regulating TRAIL expression in mice undergoing the cuff injury model. 31 In addition, FGF-2 could regulate VSMC phenotypic transformation from the contractile to the synthetic phenotype, a necessary step in the early stages of atherosclerosis. 32 Thus FGF-2 has been shown to act synergistically with platelet-derived growth factor inducing the phenotypic change in vitro. 33 In any case, and although FGF-1 levels increase in atherosclerotic plaques versus normal artery tissue, FGF-2 levels have been reported to remain normal in human atherosclerotic artery samples. 29 On the other hand, the effects of FGF-2 in endothelial cells point to a beneficial effect on atherosclerosis. Atherosclerotic disease is a progressive disorder that develops over a long period of time, triggered locally by endothelial dysfunction. FGF-2 increases proliferation and migration of endothelial cells 34 showed that pharmacological inhibition of FGF receptor signaling with a tyrosine kinase activity inhibitor attenuated atherosclerosis in apolipoprotein E null mice. 38 However, the effects observed in the former studies could be attributed to signaling of any of the 23 FGF species described so far. In experiments using specifically FGF-2, direct administration of the compound did not increase neointimal formation after balloon injury in pigs, 39 dogs, 40 rabbits 41 and it even decreased neointimal formation in a rat model of balloon injury 42 and in a rabbit model of poor distal runoff circulation. 43 In any case, the potential different effects of FGF-2 on experimental atherosclerosis could be explained by the different effect of the compound depending on the stage of evolution of plaque, from type I plaques with relatively normal histology and endothelial dysfunction, to complicated type VI plaques with thrombus. Thus, in early stages, increased FGF-2 levels can prevent the formation of plaque by reducing endothelial dysfunction. 36 By contrast, in aadvanced lesions where endothelial dysfunction is no longer an issue, FGF-2 promitogenic actions can induce plaque growth and even rupture by increasing the density of vasa-vasorum and MMP synthesis. 44, 45 In our study, lower FGF-2 levels are associated with the appearance of new plaques, but were not associated with the baseline presence of atheroma plaques, agreeing with a protective role of FGF-2 in the early stages of atheroma plaque formation. Indeed, clinical trials using FGF-2 as a treatment for revascularization have not shown any effect aggravating atherosclerotic disease. 46, 47 Our results disclosing a higher odds ratio (OR) for atheromatosis progression in CKD stages 4-5 and dialysis than in stage 3 patients may appear discordant with those of Rigatto et al 48 observing lower progression of atheromatosis in later CKD stages. In our study, the OR for atheromatosis progression was higher in stages 4-5 and dialysis compared with stage 3 patients. However, the design of both studies differ, and those differences may account for the discrepancies. First, our cohort specifically excluded CKD patients with previous cardiovascular disease, while one third of patients in Rigatto's cohort, had a previous cardiovascular event. Furthermore, our study explored the femoral territories, which were not tested in Rigatto´s study. Finally, a possible interaction between FGF-2 levels and CKD stage could also explain the discrepancy, although that interaction was tested and disregarded as non-significant.
Another result from our study shows that FGF-2 levels are lower in more severe CKD stages, reaching very low levels in dialysis patients. There is little information about the role of FGF-2 in CKD. Experimental data show that FGF-2 could be a therapeutic tool to reduce CKD. FGF-2 administration reduces functional and structural damage in experimental CKD. 49 Furthermore, FGF-2 mediates the improvement of renal function induced by the administration of mesenchymal stem cells in a rat model of CKD. 50 Thus, FGF-2 could have a potential role in the progression of CKD, although further research is warranted.
The main strength of this study is the relatively large number of patients with longitudinal observations, which allows us to make associations controlling for multiple confounders. A second strength is that the vascular exploration was performed by the same team and evaluated by a single reader. Nevertheless, our study also has some limitations. The main one is that, out of the total sample of the patients followed for atherosclerosis progression, only a portion had available plasma sample to measure FGF-2 levels. Therefore, the subpopulation might not be representative of the full cohort, as some parameters differed between patients with available sample and the rest. However, the number of patients is still high enough to adjust for many potential confounding factors. Furthermore, patients that died or suffered a cardiovascular event were also unavailable for the follow up visit, alongside patients that underwent a kidney transplant. Therefore, we can not exclude survival bias, since individuals with poor CV health were excluded. Another limitation of the study is the fact that the detection method is a multiplex assay, and results should be validated with a method specific for the FGF-2. 
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